- Home
- IVA
as 07-26-2024 4:00pm EST
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
| Founded: | 2011 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 140.3M | IPO Year: | 2020 |
| Target Price: | $18.00 | AVG Volume (30 days): | 12.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.15 - $4.75 | Next Earning Date: | 09-26-2024 |
| Revenue: | $25,736,667 | Revenue Growth: | 172.47% |
| Revenue Growth (this year): | -87.46% | Revenue Growth (next year): | 360.85% |
Latest Inventiva S.A. American Depository Shares News
IVA Breaking Stock News: Dive into IVA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
GlobeNewswire
7 days ago
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
GlobeNewswire
9 days ago
Inventiva announces a €20.1 million issuance of royalty certificates
Clinical Trials Arena
19 days ago
Inventiva reports updates from MASH/NASH treatment study
MT Newswires
21 days ago
Inventiva Looking to Raise Additional Funds to Extend Cash Runway
GlobeNewswire
21 days ago
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
GlobeNewswire
a month ago
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
GlobeNewswire
a month ago
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
Compare IVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IVA Inventiva S.A. American Depository Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.